Inspra

Eplerenone, the active ingredient in Inspra, is a mineralocorticoid receptor antagonist presented as an oral dosage form for oral use. It reduces sodium and water retention, helping to lower blood pressure and improve outcomes in patients with hypertension and heart failure.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Inspra (eplerenone) acts on the mineralocorticoid pathway to manage conditions related to fluid overload and elevated blood pressure.

- Hypertension: helps lower blood pressure by antagonizing aldosterone‑mediated sodium retention. - Heart failure: improves cardiac function and reduces hospitalisation risk by decreasing fluid accumulation.

Eplerenone may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Hyperkalemia: elevated blood potassium levels. - Dizziness or light‑headedness. - Headache. - Gastrointestinal discomfort such as nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Acute renal impairment or worsening kidney function. - Allergic reactions including angioedema or severe rash.

When prescribing or dispensing eplerenone, consider the following precautions to ensure safe use.

- Renal function: assess kidney function before initiation and monitor periodically. - Serum potassium: check potassium levels prior to therapy and during treatment. - Concomitant drugs: avoid use with strong potassium‑sparing agents. - Pregnancy and lactation: use only if benefits outweigh risks. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Eplerenone can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - ACE inhibitors or ARBs: increase risk of hyperkalemia and renal dysfunction. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise eplerenone plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and affect kidney function. - Spironolactone: additive mineralocorticoid blockade may increase potassium.